The shadow of generic rivalry has long loomed above copyright’s famous drug, PDE5 Inhibitor, triggering questions about the future of connected medicinal investments. While early years saw impressive gains, the intellectual property expiration has created the way for cheaper alternatives, potentially diminishing earnings and creating a real dange